CYBN250117C10000
- 0.75
- 0.000.00%
Cybin Newsroom
Cybin Highlights 12-Month Efficacy Results From CYB003 Psilocin Program And DMT Drug-Drug Interaction Study At ACNP Annual Meeting
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Facet Life Sciences Named Regulatory Partner for Cybin's Neuropsychiatry Therapeutics Development Pipeline
Cybin to Discuss Breakthrough Treatments at Fireside Chat
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
Cybin Inc. Advances in Mental Health Treatments
CCORF Maintains Cybin(CYBN.US) With Buy Rating, Maintains Target Price $86
Optimistic Buy Rating for Cybin: Promising CYB003 Phase 2 Results and Market Potential
HC Wainwright & Co. Reiterates Buy on Cybin, Maintains $190 Price Target
Sector Update: Health Care Stocks Mixed Premarket Monday
Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
NYSE American Net Change Percentage Gainers & Losers
RFK and the 'MAHA Trade': Vaccine Makers Down, Psychedelic Shares up
Cybin Is Maintained at Buy by Canaccord Genuity
Cybin Analyst Ratings
CCORF Maintains Cybin(CYBN.US) With Buy Rating, Cuts Target Price to $86
A. G. P. Initiates Cybin(CYBN.US) With Buy Rating, Announces Target Price $25
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
Express News | Cybin Inc : Canaccord Genuity Cuts Target Price to $86 From $96